Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The transcription factor Spi-1/PU.1 interacts with the potential splicing factor TLS

M Hallier1, A Lerga, S Barnache

  • 1INSERM U 248, Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05, France.

The Journal of Biological Chemistry
|March 28, 1998
PubMed
Summary

Spi-1/PU.1, a key transcription factor in blood cell development, interacts with TLS, a tumor-associated protein. This interaction impacts Spi-1/PU.1

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia.

Cell death and differentiation·2013
Same author

Suppression and restoration of v-SRC expression in rsv transformed-cells after transfection with N-ras and its antagonist.

International journal of oncology·2011
Same author

Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.

Oncogene·2006
Same author

Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.

Oncogene·2005
Same author

Alterations of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways in the erythropoietin-independent Spi-1/PU.1 transgenic proerythroblasts.

Blood·2001
Same author

Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts.

Oncogene·2001

Area of Science:

  • Molecular Biology
  • Hematopoiesis
  • Oncology

Background:

  • Spi-1/PU.1 is an Ets transcription factor crucial for myeloid and B lymphoid differentiation.
  • Dysregulation of Spi-1/PU.1 is implicated in Friend erythroleukemia and blocks terminal differentiation.
  • Spi-1/PU.1 exhibits RNA-binding capabilities and influences splicing processes.

Purpose of the Study:

  • To investigate the in vivo interaction between Spi-1/PU.1 and the RNA-binding protein TLS.
  • To elucidate the functional consequences of the Spi-1/PU.1 and TLS interaction on gene regulation and splicing.
  • To explore the potential role of altered pre-mRNA splicing in erythroleukemia transformation.

Main Methods:

  • In vivo interaction studies between Spi-1/PU.1 and TLS.

Related Experiment Videos

  • Assessment of Spi-1/PU.1 DNA-binding and transactivation activities in the presence of TLS.
  • Analysis of TLS-mediated effects on E1A pre-mRNA splicing and Spi-1/PU.1's counteraction.

    • Main Results:

    • Spi-1/PU.1 directly interacts with TLS in vivo.
    • TLS binding reduces Spi-1/PU.1's DNA-binding and transactivation capabilities.
    • TLS promotes distal 5' splice site usage in E1A pre-mRNA splicing, an effect counteracted by Spi-1.

    Conclusions:

    • The interaction between Spi-1/PU.1 and TLS modulates their respective functions in DNA binding and splicing.
    • Spi-1/PU.1's influence on alternative pre-mRNA splicing may contribute to erythroblastic cell transformation.
    • TLS acts as a splicing factor, influencing alternative splicing events in a manner opposed by Spi-1.